EVG vs SRBK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
EVG presents as a deep-value play with a stable Piotroski F-Score of 6/9, trading significantly below both its Graham Number ($16.79) and Intrinsic Value ($32.45). While the fund exhibits strong profitability metrics and a highly attractive 8.20% dividend yield, it is hampered by negative revenue growth (-11%) and a completely bearish technical trend (0/100). The disconnect between the fundamental value and the market price suggests a value trap risk or a significant lag in market recognition. Overall, the stability of the balance sheet is offset by poor momentum and declining top-line growth.
SRBK presents a significant divergence between its current market price and its fundamental performance. While the Piotroski F-Score of 4/9 indicates stable health and the Price-to-Book ratio (0.73) suggests an asset-based discount, the company is suffering from severe earnings decay with a -18.30% Q/Q earnings growth and a 0/4 track record of beating estimates. The current price of $18.03 is trading at a premium to its intrinsic value ($3.78) and is sitting at a 52-week high despite a critically bearish technical trend score of 10/100. This suggests a 'valuation trap' where the stock is priced for growth that is not manifesting in the financial statements.
Compare Another Pair
Related Comparisons
EVG vs SRBK: Head-to-Head Comparison
This page compares Eaton Vance Short Duration Diversified Income Fund (EVG) and SR Bancorp, Inc. (SRBK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.